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Prevalence of clinically significant red blood 
cell alloantibodies in pregnant women at a 
large tertiary-care facility
H.M. Smith, R.S. Shirey, S.K. Thoman, and J.B. Jackson
More than 50 red blood cell (RBC) alloantibodies are known 
to cause hemolytic disease of the fetus and newborn (HDFN). 
Although Rh immune globulin (RhIG) prophylaxis has 
significantly reduced the incidence of pregnancies complicated by 
anti-D, the need to detect and monitor maternal alloantibodies 
capable of causing HDFN is still a concern. The prevalence and 
specificity of these alloantibodies were determined. In this 
retrospective study, the prevalence and specificities of unexpected 
RBC alloantibodies known to cause HDFN in pregnant women 
at a tertiary-care facility during a 5-year period were compiled 
and analyzed. Patient selection was carried out by computerized 
search of patient data based on an obstetric location and the 
presence or history of RBC antibody between January 1, 2007, 
and December 31, 2011. The information was organized by ABO 
and D status of the patient, antibody specificity, and transfusion 
needs. Of the 8894 obstetric patients identified during the 5-year 
period, 264 (3.0%) had one or more unexpected RBC antibodies. 
Of these 264 women, 107 (40.5%), or 1.2 percent overall, had an 
alloantibody known to cause HDFN, with a total of 15 different 
alloantibodies identified. The most common alloantibody found 
was anti-E (n = 33), followed by anti-M (n = 26) and anti-D (n 
= 20). In pregnancies of D– women, the most common clinically 
significant antibodies found were anti-D (n = 20), anti-C (n = 11), 
and anti-E (n = 2). In pregnancies of D+ women, the most common 
antibodies were anti-E (n = 31), anti-M (n = 25), and anti-K (n 
= 16). A total of eight pregnancies with alloantibodies required 
intrauterine transfusions with the specificities of anti-D; anti-D,-C 
(n = 2); anti-D,-C,-E; anti-D,-C,-K; anti-D,-C,-Jkb; anti-D,-S; and 
anti-E,-c. At a large academic tertiary-care center, approximately 
1 in 83 obstetric patients had one or more RBC alloantibodies 
capable of causing HDFN. Anti-E, -M, and -D were the most 
frequent specificities, respectively. Immunohematology 
2013;29:127–130.
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Hemolytic disease of the fetus and newborn (HDFN) 
results from the destruction of fetal and newborn red blood 
cells (RBCs) targeted by maternal RBC alloantibodies that 
have the capability of crossing the placenta and entering the 
fetal circulation. Directed to inherited paternal RBC antigen(s), 
these antibodies are able to bind to the corresponding antigens, 
marking them for destruction by the fetal spleen, resulting 
in fetal distress. There are more than 50 RBC alloantibodies 
that have the capability of crossing the placenta and causing 
HDFN, with anti-D followed by anti-c and anti-K having the 
highest probability of causing severe HDFN.1,2
Although advances have been made in the past 50 years, 
including the implementation of Rh immune globulin (RhIG) 
to prevent anti-D HDFN in the 1960s, HDFN caused by anti-D 
as well as by non-D antibodies still remains a serious concern. 
Because women can be alloimmunized to RBC antigens 
through transfusion and pregnancy, it is still necessary to 
detect and monitor maternal alloantibodies that may put the 
fetus at risk for HDFN.3
The prevalence of alloantibodies in pregnancy has been 
investigated in multiple studies during the past few years in 
various countries, such as Sweden, Nigeria, Croatia, and the 
Netherlands.1,4–6 A compilation of similar data from the United 
States is limited. Although the frequency of alloantibodies at 
our institution would not necessarily reflect the prevalence in 
the United States, an evaluation of such data at a large hospital 
with high-risk obstetric patients would help to reiterate the 
importance of screening for and monitoring those pregnancies 
that present with antibodies that may put the fetus at risk 
for HDFN. Therefore, we determined the prevalence and 
specificity of unexpected maternal RBC alloantibodies 
associated with HDFN in a large obstetric population at our 
hospital. The associations between ABO group and D type 
and the presence of clinically significant RBC alloantibodies 
associated with HDFN were also determined.
Materials and Methods
Data collection and analysis were performed at the Johns 
Hopkins Hospital in Baltimore, Maryland, and included all 
women seen in the hospital’s obstetrics department between 
January 1, 2007, and December 31, 2011, who had an ABO 
and D type and antibody screen performed. Patient selection 
was carried out by computerized search of patient data based 
on the parameters of obstetric location and the presence of 
RBC alloantibody. Only female patients who had a record of, 
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or presented with, one or more RBC alloantibodies during 
pregnancy were included in the search. Each patient’s ABO and 
D type and any RBC transfusions given were then compiled 
from the blood bank database and analyzed. The identification 
of passive maternal alloantibody in the baby was detected by 
a positive direct or indirect antiglobulin test. For those babies 
with passive antibody of maternal origin, the occurrence of 
transfusion of antigen-negative units was determined.
The methods used to detect the antibodies included routine 
screening and antibody identification in accordance with AABB 
guidelines.2,3 A history of RhIG  administration was verified 
by review of medical records at the time of presentation. All 
mothers with only anti-D as a result of RhIG were excluded 
from the study. Patients with demonstrable alloantibodies or 
a history of demonstrable alloantibodies were included. The 
antibodies were then evaluated and sorted according to their 
ability to cause HDFN as outlined in the AABB guidelines for 
prenatal and perinatal immunohematology.3
The total number of antenatal cases was determined using 
the institution’s laboratory information system. All duplicate 
samples on the same patient and all cancelled and rejected 
specimens were removed from the total, and only specimens 
with completed ABO and D types and antibody screens were 
included. Approximately 9 percent of the women identified 
ended up delivering elsewhere, but they were included in the 
analysis.
The association between ABO type and D types and the 
presence of clinically significant RBC alloantibodies associated 
with HDFN was determined using χ2 statistics for proportion 
and frequency comparisons.
Results
Between January 1, 2007, and December 31, 2011, 8894 
different obstetric patients were typed for ABO and D and 
screened for RBC alloantibodies. Approximately 91 percent 
of these women delivered at Johns Hopkins Hospital, but all 
8,894 women were included in the analysis. During this same 
period, there were 9,734 deliveries at Johns Hopkins Hospital 
with approximately 20 percent being one or more repeat 
deliveries from the same woman.
The percentage of the 8894 women who had clinically 
significant alloantibodies by group O, A, B, and AB blood types 
were 1.1 percent, 1.4 percent, 1.2 percent, and 1.5 percent, 
respectively (Fig. 1). No significant association (p = 0.64) was 
found between the ABO group and the presence of clinically 
significant RBC alloantibodies associated with HDFN.
Of the 8894 obstetric patients screened, 8147 (91.6%) 
were D+ (Fig. 2) and 747 (8.4%) were D–. A total of 264 (3.0%) 
women demonstrated or had a history of one or more RBC 
antibodies at the time of pregnancy. Of the 264 patients with 
antibodies, 157 (59.5%) had antibodies typically considered 
clinically benign in regard to HDFN, and 107 (40.5%), or 1.2 
percent overall, had at least one antibody known to cause 
HDFN.3 The most frequent antibody identified was anti-E (n = 
33), followed by anti-M (n = 26) and anti-D (n = 20). A total of 
145 antibodies, with 15 different specificities, that are known 
to cause HDFN were identified. Of the 107 patients with 
antibodies known to cause HDFN, 28 (26.2%) had multiple 
antibody specificities; a breakdown of those antibodies is 
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Fig. 1 Distribution of obstetric patients with red blood cell antibodies between January 1, 2007, and December 31, 2011, by ABO group. 
HDFN = hemolytic disease of the fetus and newborn.
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Of the 8147 D+ women, 82 (1.0%) had one or more 
alloantibodies capable of causing HDFN compared with 
25 (3.3%) of the 747 D– women (p < 0.0001). Of the 82 D+ 
pregnant women with antibodies, anti-E (n = 31), anti-M (n = 
25), and anti-K (n = 16) were the most frequent. Anti-D was 
seen in 20 of the 25 pregnancies in D– women with antibodies, 
followed by anti-C (n = 11) and anti-E (n = 2).
Of those obstetric cases identified in the study with 
antibodies known to cause HDFN, 14 women required RBC 
transfusions during their pregnancy or at delivery because of 
sickle cell disease (n = 5) or postpartum hemorrhage (n = 9). 
Eight women required one or more intrauterine transfusions 
(IUTs). The antibody specificities requiring an IUT were 
anti-D; anti-D,-C (n = 2); anti-D,-C,-E; anti-D,-C,-K; anti-D,-
C,-Jkb; anti-D,-S; and anti-E,-c. The most frequent antibody 
was anti-D, in seven of the eight pregnancies requiring 
an IUT.
Approximately 91 percent, or 7457, of the pregnant 
women in this study delivered at our facility. Of those infants 
born at our institution, 24, or 0.3 percent, were identified as 
having passive alloantibody of maternal origin. Anti-D (n 
= 17), with or without other antibody specificities, was the 
most common. Of those infants with passive alloantibody of 
maternal origin, five infants received transfusion of antigen-
negative RBCs within 24 hours of birth. All five infants 
had passively acquired anti-D, with four of five infants 
demonstrating one to two additional alloantibodies (anti-S, 
anti-C, anti- K, or anti-Jkb).
Discussion
This study revealed that of the 8894 pregnant women 
screened, the percentage of women who demonstrated or had 
a history of an RBC alloantibody at the time of pregnancy 
was 3.0 percent, with 1.2 percent of women having at least 
one alloantibody known to cause HDFN. The most frequent 
alloantibody found in patients with at least one antibody 
known to cause HDFN was anti-E (30.8%), followed by 
anti-M (24.3%) and anti-D (18.7%). In one study evaluating 
the prevalence of antibodies in Dutch women, anti-E was also 
found to be the most common antibody detected.7
Nearly half (46.8%) of these women typed as blood group 
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Fig. 2 Distribution of obstetric patients with red blood cell antibodies 
between January 1, 2007, and December 31, 2011, by D type. HDFN 
= hemolytic disease of the fetus and newborn.
Table 1. Antibody specificities in pregnant women with clinically 
significant antibodies between January 1, 2007, and  
December 31, 2011.
Antibody specificity
# of pregnancies in D+ women 
with antibody specificity
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typing as blood groups A, B, and AB, respectively, with 91.6 
percent typing as D+. These percentages are similar to those 
in a black non-Hispanic population in the United States 
as reported by Garratty et al., in which 50.2 percent, 25.8 
percent, 19.7 percent, and 4.3 percent typed as blood groups 
O, A, B, and AB respectively, with 92.9 percent typing as D+.8 
These findings at our institution are most likely attributable to 
the fact that approximately 62.5 percent of the patients who 
deliver at our hospital are African American and 4.9 percent 
are Asian American.
In our study, 1.0 percent of D+ women had one or more 
alloantibodies known to cause HDFN compared with 3.3 
percent of D– women. The most common alloantibodies in 
D+ women with at least one antibody known to cause HDFN 
were anti-E (37.8%), anti-M (30.5%), and anti-K (19.5%); in 
D– women they were anti-D (80%), anti-C (44.0%), and anti-E 
(8%).
Five infants required transfusion of antigen-negative units 
within 24 hours of birth, and eight women required at least 
one IUT. Anti-D was implicated in seven of eight (87.5%) of the 
IUT cases, which is comparable to the 85 percent of IUT cases 
in which it was implicated in a previous study,9 although the 
numbers are small. Nearly all the cases requiring transfusion 
in which HDFN was implicated involved Rh antibodies and 
multiple antibody specificities, which complicated both the 
identification and monitoring of those antibodies and the 
providing of antigen-negative units.
Although rare, there have been reports of anti-M causing 
HDFN.10 For this reason, in this study all pregnancies with 
anti-M were considered to have the potential to cause HDFN. 
There were no cases in this study in which an IUT was required 
because of anti-M.
The most common alloantibody known to cause HDFN 
found in pregnancy in this study was anti-E, followed by 
anti-M and anti-D. Despite efforts to eliminate HDFN caused 
by anti-D, that alloantibody remains the third most common 
one found in pregnant women and the most common antibody 
found in D– pregnant women at our institution. The manner 
in which D alloimmunization occurred in these patients was 
beyond the scope of our study.
It is possible that the 1.2 percent prevalence of RBC 
alloantibody clinically significant for HDFN in our obstetrics 
population is higher than that found in the general obstetrics 
population in the United States. Given that Johns Hopkins 
Hospital is a tertiary-care center, it is likely that a proportion of 
obstetric patients were referred from other hospitals because 
they were known to be alloimmunized and thus at high risk, 
resulting in a higher prevalence. Also, the number of women 
and babies requiring transfusion in this report is likely an 
underestimate, as approximately 9 percent of the 8894 
pregnant women screened delivered elsewhere. Nevertheless, 
these findings help to reinforce the importance of educating 
pregnant women and physicians concerning the risks of 
HDFN and the need to detect and monitor alloantibodies, 
not only anti-D but also other alloantibodies known to cause 
HDFN in pregnant women.
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